Proteogenomic discovery of RB1 -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets
Science Advances · 28.03.2025 · 11 (13)
DOI: 10.1126/sciadv.adq9495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 28.03.2025. Verfasst von Jacopo Iacovacci und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Hauptthemen laut MEDLINE: Retinoblastoma Binding Proteins, Proteogenomics, Neoplasms, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Genomic defects caused by truncating mutations or deletions in the Retinoblastoma tumor suppressor gene ( RB1 ) are frequently observed in many cancer types leading to dysregulation of the RB pathway. Here, we propose an integrative proteogenomic approach that predicts cancers with dysregulation in the RB pathway. A subset of these cancers, which we term as “RBness,” lack RB1 genomic defects and yet phenocopy the transcriptional profile of RB1 -defective cancers. We report RBness as a pan-cancer phenomenon, associated with patient outcome and chemotherapy response in multiple cancer types, and predictive of CDK4/6 inhibitor response in estrogen-positive breast cancer. Using RNA interference and a CRISPR-Cas9 screen in isogenic models, we find that RBness cancers also phenocopy synthetic lethal vulnerabilities of cells with RB1 genomic defects. In summary, our findings suggest that dysregulation of the RB pathway in cancers lacking RB1 genomic defects provides a molecular rationale for how these cancers could be treated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
- Data Science Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano 20133, Italy.
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK.
ORCID-Profile: Jacopo Iacovacci, Fatemeh Ahmadi Moughari, Rachael Natrajan, Christopher J Lord, Syed Haider
Zitieren
APA
Iacovacci, J., Brough, R., Moughari, F. A., Alexander, J., Kemp, H., Tutt, A. N. J., Natrajan, R., Lord, C. J., & Haider, S. (2025). Proteogenomic discovery of RB1 -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets. Science Advances, 11(13). https://doi.org/10.1126/sciadv.adq9495
Vancouver
Iacovacci J, Brough R, Moughari FA, Alexander J, Kemp H, Tutt ANJ, et al. Proteogenomic discovery of RB1 -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets. Science Advances. 2025;11(13). doi:10.1126/sciadv.adq9495
BibTeX
@article{Iacovacci2025,
author = {Iacovacci, Jacopo and Brough, Rachel and Moughari, Fatemeh Ahmadi and Alexander, John and Kemp, Harriet and Tutt, Andrew N J and Natrajan, Rachael and Lord, Christopher J and Haider, Syed},
title = {Proteogenomic discovery of RB1 -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {13},
doi = {10.1126/sciadv.adq9495}
}
EUVIMED